CILAZAPRIL ANHYDROUS

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C22H31N3O5
Molecular Weight	417.4986
Optical Activity	UNSPECIFIED
Defined Stereocenters	3 / 3
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@H]2CCCN3CCC[C@H](N3C2=O)C(O)=O

InChI

InChIKey=HHHKFGXWKKUNCY-FHWLQOOXSA-N

InChI=1S/C22H31N3O5/c1-2-30-22(29)18(13-12-16-8-4-3-5-9-16)23-17-10-6-14-24-15-7-11-19(21(27)28)25(24)20(17)26/h3-5,8-9,17-19,23H,2,6-7,10-15H2,1H3,(H,27,28)/t17-,18-,19-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C22H31N3O5
Molecular Weight	417.4986
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	3 / 3
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1712267
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/7700063 | https://www.ncbi.nlm.nih.gov/pubmed/1532534

Cilazapril (Vascace and Dynorm are brand names in a number of European countries) is an angiotensin converting enzyme (ACE; kininase II) inhibitor. It competes with angiotensin I for binding at the angiotensin-converting enzyme, blocking the conversion of angiotensin I to angiotensin II. Cilazapril is a prodrug that is hydrolyzed after absorption to its main metabolite cilazaprilat. The half-life (30–50 hours) of cilazapril allows for once daily dosing unless the hypertension is severe. Cilazapril is used for the treatment of hypertension, congestive heart failure, post-myocardial infarction, and some other indications. Adverse events were mostly observed within the first 8-16 weeks of treatment, with headache, dizziness, fatigue, nausea, cough and chest pain being the most frequent.

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Angiotensin-converting enzyme 97 Target ID: CHEMBL1808 Sources: https://www.ncbi.nlm.nih.gov/pubmed/1382157 \| https://www.ncbi.nlm.nih.gov/pubmed/10205231 \| https://www.ncbi.nlm.nih.gov/pubmed/10398211	Inhibitor 8297
Angiotensin-converting enzyme 97 Target ID: CHEMBL1808 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8869081	Inhibitor 8297

Conditions

Condition	Modality	Targets	Highest Phase	Product
Hypertension 567 Sources: https://www.drugs.com/uk/vascace-5-mg-film-coated-tablets-leaflet.html	Primary		Approved 8429	Vascace Approved Use Vascace is used to treat the following: - High blood pressure (hypertension) - Chronic (long-term) heart failure. It works by making your blood vessels relax and widen. This helps to lower your blood pressure. It also makes it easier for your heart to pump blood around your body if you have chronic heart failure.
Chronic heart failure 21 Sources: https://www.drugs.com/uk/vascace-5-mg-film-coated-tablets-leaflet.html	Primary		Approved 8429	Vascace Approved Use Vascace is used to treat the following: - High blood pressure (hypertension) - Chronic (long-term) heart failure. It works by making your blood vessels relax and widen. This helps to lower your blood pressure. It also makes it easier for your heart to pump blood around your body if you have chronic heart failure.

PubMed

Title	Date	PubMed
Cilazapril prevents hypertension in spontaneously hypertensive rats.	1986 May-Jun	2425185
Enzyme immunoassay discrimination of a new angiotensin-converting enzyme (ACE) inhibitor, cilazapril, and its active metabolite.	1987 Mar	3035170
Effects of nitrendipine and cilazapril alone or in combination on hemodynamics and regional blood flows in conscious spontaneously hypertensive rats.	1988	2468061
A review of the preclinical cardiovascular pharmacology of cilazapril, a new angiotensin converting enzyme inhibitor.	1989	2527528
Anti-ischemic effects of cilazapril in patients with both hypertension and angina pectoris. Preliminary report of a pilot study.	1991	1838032
Improvement of diastolic filling in hypertensive patients treated with cilazapril.	1991	1715471
Kinin and angiotensin II receptor antagonists in rats with chronic renal failure: chronic effects on cardio- and renoprotection of angiotensin converting enzyme inhibitors.	1995 Dec	8903652
Normalization of insulin resistance in non-obese essential hypertension by cilazapril treatment.	1995 Nov	8563700
Improvement of left ventricular diastolic dysfunction in hypertensive patients 1 month after ACE inhibition therapy: evaluation by ultrasonic automated boundary detection.	1996	9248849
Angiotensin-converting enzyme inhibitor-induced angioedema: late onset, irregular course, and potential role of triggers.	1997 Apr	9188926
[Follow-up of patients with chronic aortic valve insufficiency with ACE inhibitor therapy].	1997 Dec	9499499
Angiotensin-converting enzyme inhibitor cilazapril suppresses expression of basic fibroblast growth factor messenger ribonucleic acid and protein in endothelial and intimal smooth muscle cells in a vascular injury model of spontaneous hypertensive rats.	1998 May	9640960
Effects of cilazapril on endothelial function and pulmonary hypertension in patients with congestive heart failure.	2002 Nov	12558130
Combined therapy of cilazapril and losartan has no additive effects in ameliorating adriamycin-induced glomerulopathy.	2004	15331931
[A prospective study on the cough mechanism induced by angiotensin-converting enzyme inhibitors in patients with hypertension].	2004 Sep	15498266
Nitrofurantoin-induced fulminant hepatitis mimicking autoimmune hepatitis.	2006 Oct	16968827
Impact of cilazapril on fibrinolytic system in hypertensive patients.	2008 Jan	18180626
Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited.	2008 Nov	18713951
Combination of an ACE inhibitor and indapamide improves blood pressure control, but attenuates the beneficial effects of ACE inhibition on plasma adiponectin in patients with essential hypertension.	2009 Dec	19789415

Patents

Sample Use Guides

In Vivo Use Guide

Swallow each tablet with a drink of water. It does not matter what time of day you take yablet. However, always take it around the same time. Tablet may be taken before or after a meal. High blood pressure (hypertension): The usual starting dose for adults is 1 mg per day. Chronic heart failure: The usual starting dose is 0.5 mg per day.

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Sat Dec 16 17:02:02 GMT 2023` Edited by `admin` on `Sat Dec 16 17:02:02 GMT 2023`
Record UNII	8Q9454114Q
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

CILAZAPRIL ANHYDROUS

Common Name

English

cilazapril [INN]

Common Name

English

CILAZAPRIL [MI]

Common Name

English

CILAZAPRIL [VANDF]

Common Name

English

Cilazapril [WHO-DD]

Common Name

English

RO-312848006

Code

English

(1S,9S)-9-(((S)-1-CARBOXY-3-PHENYLPROPYL)AMINO)OCTAHYDRO-10-OXO-6H-PYRIDAZINO(1,2-A)(1,2)DIAZEPINE-1-CARBOXYLIC ACID 9-ETHYL ESTER

Common Name

English

RO-31-2848/006

Code

English

ANHYDROUS CILAZAPRIL

Common Name

English

6H-PYRIDAZINO(1,2-A)(1,2)DIAZEPINE-1-CARBOXYLIC ACID, 9-((1-(ETHOXYCARBONYL)-3-PHENYLPROPYL)AMINO)OCTAHYDRO-10-OXO-, MONOHYDRATE, (1S-(1.ALPHA.,9.ALPHA.(R*)))

Common Name

English

Classification Tree Code System Code

WHO-ATC

C09BA08